A humanized FKBP8 gene knock-in animal model and its construction method

The knock-in of humanized FKBP8 gene in a mouse model through CRISPR/Cas9 technology solved the problem of lack of humanized FKBP8 gene animal model in the existing technology, and successfully constructed an animal for studying FKBP8 gene and its products. Models promote the study of FKBP8 in clinical disease pathogenesis and treatment mechanisms.

CN118853765BActive Publication Date: 2024-11-26SHENZHEN INST OF ADVANCED TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411348909.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-26
Publication Date
2024-11-26
Estimated Expiration
2044-09-26

AI Technical Summary

Technical Problem

The existing technology has not yet achieved knock-in of humanized FKBP8 gene in animal models, which limits the study of the pathogenesis and treatment mechanism of FKBP8 gene and its products in clinical diseases.

Method used

Using CRISPR/Cas9 technology, target vectors and sgRNA were designed to perform homologous recombination replacement of human FKBP8 gene, and Cas9 and target vectors were transfected into donor animals' fertilized eggs through microinjection to generate F0 chimeric animals, and then through Mating obtained an animal model with humanized FKBP8 gene knock-in in F1 generation.

Benefits of technology

A humanized FKBP8 gene knock-in mouse model was successfully constructed, and drugs targeting FKBP8 gene and its products were screened on animal models or studying the pathogenesis and treatment mechanisms related to FKBP8 gene and its products were studied.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118853765B_ABST
    Figure CN118853765B_ABST
Patent Text Reader

Abstract

The present invention provides a method for constructing a humanized FKBP8 gene knock-in animal model, comprising: (1) constructing a targeting vector for humanized FKBP8 gene knock-in, and transfecting the targeting vector, Cas9, and sgRNA into a fertilized egg of a donor animal; (2) transplanting a viable fertilized egg cell into the oviduct of a pseudo-pregnant animal to obtain an F0 generation animal, and identifying the F0 generation animal. An animal that is positive for homologous recombination is a chimeric animal; (3) mating the chimeric animal with a wild-type animal to obtain an F1 generation animal and identifying the F1 animal that is positive for homologous recombination is a humanized FKBP8 gene knock-in animal. The construction method provided by the present invention adopts the humanized FKBP8 gene sequence to replace the donor animal FKBP8 gene sequence to achieve the purpose of humanizing the donor animal FKBP8 gene, and successfully establishes a humanized FKBP8 gene knock-in animal model, which can be used to screen drugs targeting the FKBP8 gene and its products on the animal model or to study the pathogenesis and treatment mechanism of the FKBP8 gene and its products in related clinical diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of bioengineering, and in particular relates to a humanized FKBP8 gene knock-in animal model and a construction method thereof. Background Art

[0002] FKBP8 belongs to the FK506 binding protein (FKBPs) family. Members of this protein family act as peptidyl-prolyl cis-trans isomerases (PPIase) and play a role in immune regulation and basic cellular processes involving protein folding and transport. They are involved in biological processes such as neuronal fate, mitochondrial autophagy, and cell apoptosis.

[0003] Mice have a short life cycle and are genetically similar to humans. They are the most intensively studied mammalian model organisms in genomics, transcriptomics, proteomics and phenotypes, and are usually the first choice for mammalian model organisms. Using clustalw for sequence alignment, it was found that the FKBP8 gene in mice and humans is highly unconserved (its conservation is only 37.96%). More and more studies have found the importance of the FKBP8 gene and its products in clinical diseases. Therefore, it is necessary to construct a human FKBP8 gene knock-in animal model so that researchers can further study the role of the FKBP8 gene and its products in the pathogenesis and treatment of related clinical diseases.

[0004] CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a bacterial defense mechanism that degrades invading viral DNA and other foreign DNA. The CRISPR / Cas9 system derived from Streptococcus pyogenes is currently the most commonly used one. CRISPR / Cas9 technology has been successfully used in bacteria, yeast, plants, fish and mammals, and is the most effective gene editing technology to date. There are currently no studies on humanized FKBP8 gene knock-in animal models. Summary of the invention

[0005] The purpose of the present invention is to construct a humanized FKBP8 gene knock-in animal model to study the pathogenesis and therapeutic targets of human disease models.

[0006] To this end, the present invention provides a method for constructing a humanized FKBP8 gene knock-in animal model, comprising the following steps:

[0007] (1) Construct a targeting vector for knocking in the humanized FKBP8 gene, and transfect the targeting vector, Cas9, and sgRNA into the fertilized eggs of donor animals;

[0008] (2) Transplanting viable fertilized oocytes into the oviducts of pseudopregnant animals to obtain F0 generation animals, and identifying the F0 generation animals. Animals that are positive for homologous recombination are chimeric animals;

[0009] (3) The chimeric animals are mated with wild-type animals to obtain F1 animals and identify them. The F1 animals that are positive for homologous recombination are humanized FKBP8 gene knock-in animals.

[0010] Specifically, the above step (1) is specifically as follows: designing a targeting strategy based on the EGE system developed by CRISPR / Cas9, using the extracellular region of the human FKBP8 gene to replace the extracellular region of the donor animal FKBP8 gene, and designing sgRNAs in Exon2 and Exon8 of the donor animal FKBP8 gene respectively; designing sgRNAs in the 5' and 3' target regions, detecting in vitro activity, selecting sgRNAs based on sgRNA specificity and cleavage position, and in vitro transcribing sgRNAs and Cas9 to prepare RNA for microinjection; constructing a recombinant targeting vector according to the targeting plan, and transfecting the recombinant targeting vector, Cas9, and sgRNAs into the fertilized eggs of the donor animal.

[0011] Specifically, in the above step (1), 4 sgRNAs are designed in the 5' target region, and the sequences are shown in SEQ ID NO.1-4; 4 sgRNAs are designed in the 3' target region, and the sequences are shown in SEQ ID NO.5-8; the 5' target site and 3' target site with the highest activity are selected for the next step of the experiment.

[0012] Specifically, the most active 5' target site EGE-HJL-0170-A-sgRNA3 sequence in the above step (1) is shown as SEQ ID NO.3; the most active 3' target site EGE-HJL-0170-A-sgRNA7 sequence is shown as SEQ ID NO.7.

[0013] Specifically, the above step (1) is completed by UCA TM The sgRNA activity was tested in vitro.

[0014] Specifically, in the above step (2), PCR is used to identify the genotype of the F0 generation animals; the primer sequences are shown in SEQ ID NOs. 9-12.

[0015] Specifically, in the above step (3), the F1 generation animals are subjected to PCR and Southern blot identification; the DNA of the F1 generation animals identified as positive by PCR is subjected to Southern blot detection and sequencing to confirm correct recombination and no random insertion, and the humanized FKBP8 gene knock-in animal model is successfully constructed.

[0016] Specifically, the above-mentioned animal is a mouse.

[0017] Compared with the prior art, the present invention has the following advantages and beneficial effects:

[0018] The method for constructing the humanized FKBP8 gene knock-in animal model provided by the present invention uses the humanized FKBP8 gene sequence to replace the donor animal FKBP8 gene sequence to achieve the purpose of humanizing the donor animal FKBP8 gene, and successfully establishes a humanized FKBP8 animal model, which can be used to screen drugs targeting the FKBP8 gene and its products or to study the pathogenesis and treatment mechanisms related to the FKBP8 gene and its products on the animal model.

[0019] The present invention will be further described in detail below with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 It is a targeting strategy for preparing a humanized knock-in mouse model of FKBP8 based on the EGE system developed by CRISPR / Cas9.

[0021] Figure 2 This is the Southern blot screening strategy for F1 generation positive mice.

[0022] Figure 3 This is the activity detection result of Cas9 / sgRNA.

[0023] Figure 4 It is an enzyme digestion identification and sequencing solution.

[0024] Figure 5 It is a targeting vector map.

[0025] Figure 6 This is the primer design strategy for F0 generation mice.

[0026] Figure 7 This is the result of the tail genotype identification of the F0 generation of mice (Primers: EGE-HJL-0170-AL-GT-F / EGE-HJL-0170-AL-GT-R).

[0027] Figure 8 This is the result of tail genotype identification of F0 generation mice (Primers: EGE-HJL-0170-AR-GT-F / EGE-HJL-0170-AR-GT-R).

[0028] Fig. 9 This is the result of the F1 generation mouse tail genotype identification (Primers: EGE-HJL-0170-AL-GT-F / EGE-HJL-0170-AL-GT-R).

[0029] Fig.10 This is the result of the F1 generation mouse tail genotype identification (Primers: EGE-HJL-0170-AR-GT-F / EGE-HJL-0170-AR-GT-R).

[0030] Fig.11 This is the Southern blot result of F1 mice. DETAILED DESCRIPTION

[0031] The technical scheme in the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments. Although the representative embodiments of the present invention have been described in detail, it will be understood by those skilled in the art that various modifications and changes can be made to the present invention without departing from the scope of the present invention. Therefore, the scope of the present invention should not be limited to the embodiments, but should be limited by the attached claims and their equivalents.

[0032] The effects of the humanized FKBP8 gene knock-in animal model and the construction method thereof of the present invention are studied below through specific examples.

[0033] Embodiment 1:

[0034] 1. Design of targeting vector

[0035] The human FKBP8 gene is on the reverse strand of chromosome 19 (NC_000019.9_c18654383-18642573, 11811 bp), the expressed protein is 412 aa in length, and there are 14 transcripts. This example refers to transcript 201. The mouse FKBP8 gene is on the positive strand of chromosome 8 (NC_000074.7_70980371-70987978, 7608 bp), the expressed protein is 402 aa in length, and there are 11 transcripts. This example refers to transcript 202.

[0036] Through homology comparison, the differences in FKBP8 gene sequences between humans and mice were accurately found, which were different in exon Exon2 and Exon8 regions. After repeated exploration and adjustment, it was found that the extracellular region of the human FKBP8 gene could be used to replace the extracellular region of the mouse FKBP8 gene, which has better homologous recombination efficiency and achieves the purpose of efficiently initiating the expression of human sequences under the mouse promoter. More importantly, the function of the human FKBP8 gene can be realized in the mouse model.

[0037] The humanized knock-in model mice were prepared using the EGE system developed by Biocytogen based on CRISPR / Cas9. sgRNAs were designed in Exon2 and Exon8 of the FKBP8 gene of C57BL / 6J mice, and the actual sizes of the 5' and 3' homology arms of the targeting vector used for homologous recombination were 1.2 kb and 1.2 kb, respectively. Figure 1 shown.

[0038] 2. Cas9 / sgRNA design

[0039] Based on the design principles of sgRNA, four sgRNAs were designed in the 5' target site and 3' target site regions, respectively, and their corresponding targeting sequences are shown in Table 1.

[0040] Table 1 sgRNA sequences (SEQ ID NO. 1-8)

[0041]

[0042] The target gene DNA sequences of different strains may be different. In order to ensure the correctness of the designed Cas9 / sgRNA, the target gene DNA sequence of C57BL / 6J mouse tail was first amplified by PCR and sequenced for verification. The verification results showed that the sgRNA target sequence was completely consistent with the standard sequence given in the Genebank database.

[0043] Adopt UCA TM The in vitro activity detection of sgRNA has the advantages of no species restriction, high throughput, wide adaptability, high sensitivity, and simplicity. TM Activity detection, combined with sgRNA specificity and cutting position, comprehensively selected EGE-HJL-0170-A-sgRNA3 (SEQ ID NO.3) and EGE-HJL-0170-A-sgRNA7 (SEQ ID NO.7) for the next step of the experiment, the test results are as follows Figure 3 shown.

[0044] 3. Preparation of RNA for Cas9 / sgRNA

[0045] EGE-HJL-0170-A-sgRNA3, EGE-HJL-0170-A-sgRNA7 and Cas9 were transcribed in vitro to prepare RNA for microinjection.

[0046] 4. Construction of targeting vector

[0047] According to the targeting scheme, the targeting vector was constructed and identified by enzyme digestion and sequencing ( Figure 4 ), confirm that the targeting vector is constructed correctly, and prepare the targeting vector for microinjection as Figure 5 shown.

[0048] 5. Microinjection

[0049] Cas9 / sgRNA and targeting vector were microinjected into mouse fertilized eggs. The birth of F0 mice after injection was as follows:

[0050]

[0051] 6. Genotype identification of F0 generation mice

[0052] Since the embryonic cleavage rate is very fast in the early stage, the F0 mice obtained are chimeras. Therefore, the F0 genotype obtained by identifying the tail of the F0 mouse is only for reference and does not necessarily mean that it is a heritable gene mutation. The heritable genotype needs to be determined after the tail of the F1 mouse is tested. For the primers and results of the F0 generation mouse identification, please refer to Tables 2-3 and Figure 6-8 shown.

[0053] Table 2 Primer information (SEQ ID NO.9-12)

[0054]

[0055] And: Table 3 Genotype identification PCR conditions

[0056]

[0057] PCR amplification and product sequencing showed that E4L0170-0001, E4L0170-0015, E4L0170-0017, E4L0170-0018 and E4L0170-0022 were positive F0 mice.

[0058] 7. Mating to obtain F1 mice

[0059] The F0 mice identified as positive were mated with wild-type mice to obtain F1 mice with stable genotypes. The mating results are as follows (showing the F1 mice obtained by mating positive F0 mice with wild-type mice):

[0060]

[0061] In order to screen gene-targeted mice with correct recombination, PCR and Southern blot methods were used to verify the F1 generation of mice.

[0062] The design principles of PCR primers are the same as those for identifying the primers for the F0 generation of mice. Figure 9-10PCR amplification showed that 1E4L0170-0001, 1E4L0170-0008, 1E4L0170-0009, 1E4L0170-0012, 1E4L0170-0013, 1E4L0170-0016, 1E4L0170-0018, 1E4L0170-0020, 1E4L0170-0022, 1E4L0170-0025, 1E4L0170-0027, 1E4L0170-0031, 1E4L0170 -0032, 1E4L0170-0033, 1E4L0170-0045, 1E4L0170-0047, 1E4L0170-0049, 1E4L0170-0050, 1E4L0170-0052, 1E4L0170-0053, 1E4L0170-0056, 1E4L0170-0058, 1E4L0170-0061, 1E4L0170-0066 and 1E4L0170-0067 are the positive F1 generation mice in the initial screening.

[0063] A Probe-A and 5'Probe-A were used to verify the positive mice of F1 generation. The Southern blot screening strategy was as follows: Figure 2 As shown, the specific design is as follows (ScaI and Eco53KI are shown as Southern blot restriction sites):

[0064]

[0065] ScaI and Eco53KI were used as restriction sites for Southern blot. 5'Probe-A was used to detect whether correct recombination occurred. If correct recombination occurred, two bands, wild type and mutant type, would appear. A Probe-A was used to detect whether there was random insertion. If there was no random insertion, a mutant type band would appear. The tail DNA of 14 F1 mice that were positive in the initial PCR screening was extracted for Southern blot detection. The results are as follows: Fig.11 shown.

[0066] Southern blot analysis showed that 1E4L0170-0056, 1E4L0170-0058, 1E4L0170-0061, 1E4L0170-0066 and 1E4L0170-0067 were all correctly recombined without random insertions.

[0067] After PCR, Southern blot and sequencing verification, 5 F1 generation positive mice were finally obtained. The specific information is as follows (showing the 5 F1 generation positive mice finally obtained after PCR, Southern blot and sequencing verification):

[0068]

[0069] This shows that this example successfully constructed a FKBP8 humanized knock-in mouse model.

[0070] The above examples are merely illustrative of the present invention and do not constitute a limitation on the protection scope of the present invention. All designs that are the same or similar to the present invention fall within the protection scope of the present invention.

Claims

1. A method for constructing a humanized FKBP8 gene knock-in mouse model, characterized in that: The following steps are involved: (1) Construct a targeting vector for knocking in the humanized FKBP8 gene and transfect the targeting vector, Cas9, and sgRNA into donor mouse fertilized eggs; (2) Transplanting viable fertilized oocytes into the oviducts of pseudo-pregnant mice to obtain F0 generation mice, and identifying the F0 generation mice. Mice that are positive for homologous recombination are chimeric mice; (3) The chimeric mice are mated with wild-type mice to obtain F1 mice and identify them. The F1 mice that are positive for homologous recombination are humanized FKBP8 gene knock-in mice; wherein: The step (1) specifically comprises: designing a targeting strategy based on the EGE system developed by CRISPR / Cas9, replacing the extracellular region of the donor mouse FKBP8 gene with the extracellular region of the human FKBP8 gene, and designing sgRNAs in Exon2 and Exon8 of the donor mouse FKBP8 gene respectively; designing sgRNAs in the 5' and 3' target regions, detecting in vitro activity, selecting sgRNAs based on sgRNA specificity and cleavage position, and in vitro transcribing sgRNAs and Cas9 to prepare RNA for microinjection; constructing a recombinant targeting vector according to the targeting scheme, and transfecting the recombinant targeting vector, Cas9, and sgRNAs into the fertilized eggs of the donor mice; In the step (1), four sgRNAs are designed in the 5' target region, and the sequences are shown in SEQ ID NO.1-4; four sgRNAs are designed in the 3' target region, and the sequences are shown in SEQ ID NO.5-8; the 5' target site and 3' target site with the highest activity are selected for the next step of the experiment; In the step (2), PCR is used to identify the genotype of the F0 generation mice; the primer sequences are shown in SEQ ID NO.9-12; The most active 5' target site EGE-HJL-0170-A-sgRNA3 sequence in step (1) is shown in SEQ ID NO.3; the most active 3' target site EGE-HJL-0170-A-sgRNA7 sequence is shown in SEQ ID NO.

7.

2. The method for constructing a humanized FKBP8 gene knock-in mouse model according to claim 1, characterized in that: In the step (3), the F1 generation mice are subjected to PCR and Southern blot identification; the DNA of the F1 generation mice identified as positive by PCR is subjected to Southern blot detection and sequencing to confirm correct recombination and no random insertion, and the F1 generation humanized FKBP8 gene knock-in mouse model is successfully constructed.